The Abbott TDx evaluated for T-uptake

G. A. Harff*  
Department of Clinical Chemistry, Academic Hospital, Free University, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

Introduction

The Abbott TDx therapeutic drug-monitoring system is based on fluorescence polarization. Polarization fluoroimmunoassay makes use of competitive binding, measuring the tracer binding directly, without the need for separation procedures. The attraction of non-radioactive polarization fluoroimmunoassay for the determination of T-uptake is that there is no radiation hazard and that the homogeneous method is very convenient.

Materials

Apparatus: TDx Therapeutic Drug Monitoring System (Abbott Laboratories, Diagnostics Division, North Chicago, Illinois, USA).

Reagents: T-uptake reagent pack, Lot No. 55-167-HC (Abbott Laboratories). T3-uptake, ¹²⁵I RIA kit, (Diagnostic Products Corporation, Los Angeles, California, USA).

Specimen: T-uptake calibrators No. 8100/911%01, Lot No. CLI (Abbott Laboratories).

Controls: RIATRAC radioassay controls: RIATRAC1, Lot No. HL4001; RIATRAC2, Lot No. HL 4002; and RIATRAC3, Lot No. HL 4003 (Becton Dickinson Immunodiagnostics, Orangeburg, New York, USA).

Fresh patients' sera from the Academic Hospital were used for the method comparison.

Results and discussion

Replication experiment

Three replication experiments—'mini', 'midi', and ' maxi'—are described by the National Committee for Clinical Laboratory Standards (NCCLS) in the proposed standard PSEP-3 [1] and these were consulted for the evaluation. The experimental design permits estimation of within-run, between-run within a day, between-run between days, and total variance. The midi and maxi experiments permit calculation of the variance excluding and including carry-over effects. The TDx therapeutic drug monitoring system measures by fluorescence polarization immunoassay. An estimation of the effects of carry-over with the TDx was considered important—it is a discrete system and the probe may contribute to carry-over. Abbott Laboratories, in their Operator's Manual [2], claim that carry-over is less than 1.5%. The midi experiment is an efficient method where three different levels control materials need to be analysed for T-uptake six times per analytical run, with two runs per day for 20 working days. This gave a total of 240 observations at each level.

| Level Imprecision | Low CV (%) | Mid CV (%) | High CV (%) |
|-------------------|------------|------------|-------------|
| Within-run        | 3.37       | 2.31       | 2.53*       |
| Between-run       | 3.43       | 1.54       | 2.83*       |
| (within a day)    | 2.79       | 1.25       | 1.27‡       |
| Between-run       | 2.62       | 1.34       | 2.10†       |
| (between days)    | 2.35       | 1.25       | 1.80†       |
| Total             | 4.45       | 2.52       | 3.31†       |

| N | Relative uptake (%) | CV (%) |
|---|---------------------|--------|
| 33 | 24.66               | 0.87   | 3.71   |
| 34 | 24.66               | 0.87   | 3.96   |
| Total 100 | 29.55 | 1.11 | 4.26 |

Note: mean concentration for the controls were 0.410 (low), 0.729 (mid) and 1.032 (high).

Table 1. Statistical analysis of data from the replication experiment.

Table 2. Within-run imprecision estimated from duplicate analyses of patients' samples.

| T3-uptake (RIA) |
|-----------------|------------|--------|
| N   | Uptake (%) | Relative uptake† | CV (%) |
| 33  | 27.07      | 1.13    | 2.31   |
| 34  | 30.26      | 0.97    | 2.25   |
| Total 100 | 31.12 | 0.96 | 2.31 |

| T-uptake (TDx) |
|-----------------|------------|--------|
| N   | Uptake (%) | Relative uptake† | CV (%) |
| 33  | 27.07      | 1.13    | 2.31   |
| 34  | 30.26      | 0.97    | 2.25   |
| Total 100 | 31.12 | 0.96 | 2.31 |

† T-uptake values expressed in unitless numbers which represent ratios relative to a normal value.

Three levels of RIATRAC radioassay controls were used to perform the midi replication experiment. The results are given in table 1. An estimate of the percentage carry-over is obtained from the sequence of observations of levels: High 1, High 2, Low 1, Low 2 and Low 1, Low 2, High 1, High 2. H2 and L2 were assumed to be unaffected by carry-over because they are preceded by samples of the same concentration. A percentage carry-over is estimated by respectively  

\[ p = \frac{(L1-L2)/(H2-L2)}{100\%} \]  

and  

\[ p = \frac{(H1-H2)/(H2-L2)}{100\%} \]  

The mean percentage (pe) of carry-over obtained from H1, H2, L1, L2 is \(-0.777\%\), with a standard error of mean (SEM) of 0.591%. Assuming

* Present address: Department of Clinical Chemistry, Academic Hospital, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.
normal distribution, the Student t test results in $t = 1.30$. At $p = 0.05$ it is impossible to reject the null hypothesis that no difference exists in the mean percentage of carry-over and null percent (mean percentage of carry-over is not significant). The sequence L1, L2, H1, H2 results in $p_e = 0.0695\%$, SEM = 0.749, $t = 0.93$. In this situation the null hypothesis cannot be rejected either and the mean percentage of carry-over is not significant.

**Comparison of methods experiment**

For the comparison of methods experiment (PSEP-4 [3]) the TDx therapeutic drug-monitoring system T-uptake results provides a measure of thyroxine binding sites in a sample. As a comparative method a T3-uptake assay, using a $^{125}$I RIA kit, was run. Due to the different methods of measuring T4-binding sites, results obtained with the T-uptake and T3-uptake are inversely related. To compare methods, the T-uptake values were mathematically transformed to percentage uptake values, according to Abbott [2], assuming a mean normal value of 29.5% (TDx transformed % uptake = 29.5/0.8(T-uptake)$^2$ + 0.2. One hundred patients’ samples were analysed in duplicate for T-uptake and T3-uptake. The data points obtained were analysed statistically with the NCCLS accuracy computer program; no data points were excluded.

The statistical analysis included calculation of within-run imprecision for each method based on duplicate analysis, and an estimate of method accuracy from regression calculation. Table 2 presents estimates of imprecision, divided into three groups according to the results in percentage uptake. Mean values are shown as average concentrations of the group. These imprecision results obtained with patient sera for T-uptake are in agreement with the within-run imprecision results obtained by the replication experiment (see table 1).

The regression analysis between the T3-uptake (x axis) and the T-uptake (y axis) resulted in a slope of 0.810 (95% confidence range: 0.781 to 0.839) and an intercept of 2.932 (95% confidence range: 2.912 to 2.952). The standard error of estimate, $S_{yy}$, is 2.52%.

It can be concluded, with respect to imprecision and accuracy, that the TDx therapeutic drug-monitoring system gives good results for T-uptake. Taking in account the facts that the method is non-radioactive, homogeneous, applicable for statistical analysis, calibration once a fortnight, the TDx is an attractive system for analysing T-uptake.

**References**

1. National Committee for Clinical Laboratory Standards, Proposed Standard PSEP-3: Protocol for Establishing Performance Claims for Clinical Chemical Methods. Replication Experiment (NCCLS, USA, 1979).
2. Abbott Laboratories, Diagnostic Division, TDx Operators Manual (Abbott Laboratories, USA, 1983).
3. National Committee for Clinical Laboratory Standards Proposed Standard PSEP-4: Protocol for Establishing Performance Claims for Clinical Methods. Comparison of Methods Experiment (NCCLS, USA, 1979).